BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22082483)

  • 1. HCV infection by cell-to-cell transmission: choice or necessity?
    Carloni G; Crema A; Valli MB; Ponzetto A; Clementi M
    Curr Mol Med; 2012 Jan; 12(1):83-95. PubMed ID: 22082483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steps and Routes of HCV Infection: The Great Promise of New Anti-Viral Targets.
    Crema A; Ponzetto A; Clementi M; Carloni G
    Curr Drug Targets; 2015; 16(7):757-70. PubMed ID: 25694122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
    Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
    J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection.
    Benedicto I; Molina-Jiménez F; Bartosch B; Cosset FL; Lavillette D; Prieto J; Moreno-Otero R; Valenzuela-Fernández A; Aldabe R; López-Cabrera M; Majano PL
    J Virol; 2009 Aug; 83(16):8012-20. PubMed ID: 19515778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.
    Fan H; Qiao L; Kang KD; Fan J; Wei W; Luo G
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28404852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.
    Perrault M; Pécheur EI
    Biochem J; 2009 Oct; 423(3):303-14. PubMed ID: 19807698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD81 large extracellular loop-containing fusion proteins with a dominant negative effect on HCV cell spread and replication.
    Grigorov B; Molle J; Rubinstein E; Zoulim F; Bartosch B
    J Gen Virol; 2017 Jul; 98(7):1646-1657. PubMed ID: 28721844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.
    Deest M; Westhaus S; Steinmann E; Manns MP; von Hahn T; Ciesek S
    Antiviral Res; 2014 Jan; 101():37-44. PubMed ID: 24211330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.
    Ding Q; von Schaewen M; Hrebikova G; Heller B; Sandmann L; Plaas M; Ploss A
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants in the Ig Variable Domain of Human HAVCR1 (TIM-1) Are Required To Enhance Hepatitis C Virus Entry.
    Kachko A; Costafreda MI; Zubkova I; Jacques J; Takeda K; Wells F; Kaplan G; Major ME
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29321304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.
    McCaffrey K; Boo I; Owczarek CM; Hardy MP; Perugini MA; Fabri L; Scotney P; Poumbourios P; Drummer HE
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
    Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
    PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus entry.
    Zeisel MB; Felmlee DJ; Baumert TF
    Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus entry and neutralization.
    Stamataki Z; Grove J; Balfe P; McKeating JA
    Clin Liver Dis; 2008 Aug; 12(3):693-712, x. PubMed ID: 18625435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry.
    Benedicto I; Molina-Jiménez F; Moreno-Otero R; López-Cabrera M; Majano PL
    World J Gastroenterol; 2011 Jun; 17(22):2683-90. PubMed ID: 21734774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.
    Falkowska E; Kajumo F; Garcia E; Reinus J; Dragic T
    J Virol; 2007 Aug; 81(15):8072-9. PubMed ID: 17507469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV Interplay with Lipoproteins: Inside or Outside the Cells?
    Cosset FL; Mialon C; Boson B; Granier C; Denolly S
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32290553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus entry: role of host and viral factors.
    Samreen B; Khaliq S; Ashfaq UA; Khan M; Afzal N; Shahzad MA; Riaz S; Jahan S
    Infect Genet Evol; 2012 Dec; 12(8):1699-709. PubMed ID: 22878095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.